Adenosine axis as a novel driver and therapeutic target in immunosuppressive microenvironment of NSCLC
10.3969/j.issn.1000-484X.2025.11.043
- VernacularTitle:腺苷轴:非小细胞肺癌免疫抑制性微环境的新兴驱动力与治疗靶点
- Author:
Kejian GONG
1
;
Wei LIU
1
Author Information
1. 吉林大学白求恩第一医院,长春 130000
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Immunotherapy;
Tumor microenvironment;
Adenosine axis
- From:
Chinese Journal of Immunology
2025;41(11):2812-2816,后插1-后插2
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer(NSCLC)is one of leading causes of cancer-related mortality worldwide.In recent years,immune checkpoint inhibitors(ICIs)have become the first-line treatment option for advanced NSCLC.Although ICIs have significantly improved the prognosis of some patients,not all individuals benefit from these therapies.The immunosuppressive tumor microenvironment(TME)is considered a key factor limiting the efficacy of ICIs.The adenosinergic axis refers to pathway in which extracellular ATP is sequentially degraded into adenosine(ADO)by enzymes and subsequently regulates immune responses through binding to ADO receptors.In TME of NSCLC,pathological conditions such as hypoxia,cell necrosis,and inflammation can lead to abnormal accumulation of ADO,thereby suppressing immune cell function and driving expansion of immunosuppressive cells.Due to its central role in immunosuppression,adenosinergic axis has become a major focus of tumor immunotherapy research.This article further explores complex interactions among ADO,its receptors and TME,proposes potential strategies for targeting adenosinergic axis to enhance antitumor immunity,evaluates the progress of early clinical studies of related pharmacological inhibitors in NSCLC,and discusses future research directions.
